TV News LIES

Sunday, Nov 23rd

Last update06:54:06 AM GMT

You are here News Health Study outcome won't sway company on eye drug

Study outcome won't sway company on eye drug

E-mail Print PDF

What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?

In the case of Genentech Inc., nothing.

The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.

More...


Most Recent Related Stories...


Federal court allows Mississippi's only abortion clinic to remain open

abortion clinic mississippiA federal appeals court said Thursday that it won’t reconsider its earlier ruling that a 2012...

Canadian couple ends up with $1M hospital bill for birth in Hawaii

Blue CrossA Canadian couple got stuck with an enormous hospital bill after their baby came nine weeks...

Dear New York City's Uninsured: Screw You, Love Governor Cuomo

Andrew CuomoBridging the gap between policy debate and real, appreciable government support, Remote Area Medical has hosted...

Eating trans fat may damage memory

transfatYet another reason to cut back on cookies: A new study shows that eating trans fat...
 
America's # 1 Enemy
Tee Shirt
& Help Support TvNewsLIES.org!
TVNL Tee Shirt
 
TVNL TOTE BAG
Conserve our Planet
& Help Support TvNewsLIES.org!
 
Get your 9/11 & Media
Deception Dollars
& Help Support TvNewsLIES.org!
 
The Loaded Deck
The First & the Best!
The Media & Bush Admin Exposed!